

**In the Claims:**

Please amend claims 14, 24, 46, 61, 72, 87, 98 and 99 as follows:

(clean version—see Version of Claims to Show Changes Made below)

B3  
14. The chimeric RSV of claim 11, wherein two or more of the M2-1, M2-2 and L genes are replaced by counterpart genes from a bovine RSV.

B4  
24. The chimeric RSV of claim 23, which is rBRSV/A2-G1F2.

B5  
46. The chimeric RSV of claim 1 which is a complete virus.

B6  
61. The immunogenic composition of claim 57, wherein the chimeric RSV elicits an immune response against both human RSV A and RSV B.

B7  
72. The isolated polynucleotide of claim 68, wherein two or more of the M2-1, M2-2 and L genes are replaced by counterpart genes from a bovine RSV.

B8  
87. The isolated polynucleotide molecule of claim 84, wherein the nucleotide modification comprises a nucleotide deletion, insertion, addition or rearrangement of a cis-acting regulatory sequence of a selected RSV gene within the chimeric RSV genome or antigenome.

B9  
98. The chimeric RSV of claim 90, wherein the vector genome or antigenome is a partial or complete HRSV or BRSV genome or antigenome and the heterologous pathogen is selected from subgroup A and subgroup B respiratory syncytial viruses.

99. The chimeric RSV of claim 98, wherein said one or more heterologous antigenic determinant(s) is/are selected from subgroup A or subgroup B respiratory syncytial virus F, G, SH and M2 proteins.